Distinctive effects of carvedilol in the non-infarct zone: Remodelling of the ligated rat heart linked to oxidative stress

Journal of International Medical Research

Volumn 37, Issue 5, 2009, Pages 1354-1364

  Zhuang, X F ^a   Yin, C Q ^b   Wang, H Y ^a   Sun, N L ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Carvedilol; Collagenases; Metoprolol; Myocardial infarction; Oxidative stress; Ventricular remodelling

Indexed keywords

ANTIOXIDANT; AUTACOID; BUNAZOSIN; CARBAZOLE DERIVATIVE; CARVEDILOL; COLLAGENASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; METOPROLOL; NEUTROPHIL COLLAGENASE; PROPANOLAMINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASODILATOR AGENT;

ACUTE DISEASE; ANIMAL; ARTICLE; DRUG COMBINATION; DRUG EFFECT; FEMALE; GEL MOBILITY SHIFT ASSAY; GENETICS; HEART; HEART INFARCTION; LIGATION; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ACUTE DISEASE; ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; CARBAZOLES; DRUG COMBINATIONS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; HEART; INFLAMMATION MEDIATORS; LIGATION; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 8; METOPROLOL; MYOCARDIAL INFARCTION; NF-KAPPA B; OXIDATIVE STRESS; PROPANOLAMINES; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASODILATOR AGENTS;

EID: 77649208006     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/147323000903700510     Document Type: Article

References (27)

1. Braunwald E: Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2159.
2. Etoh T, Joffs C, Deschamps AM, et al: Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol 2001; 281: H987-H994.
3. Martos R, Baugh J, Ledwidge M, et al: Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115: 888-895.
4. Rohde LE, Ducharme A, Arroyo LH, et al: Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999; 99: 3063-3070.
5. Frishman WH: Carvedilol. N Engl J Med 1998; 339: 1759-1765.
6. Aruoma OI: Scavenging of hypochlorous acid by carvedilol and ebselen in vitro. Gen Pharmacol 1997; 28: 269-272.
7. Lysko PG, Webb CL, Gu JL, et al: A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol 2000; 36: 277-281.
8. Yue-Chun L, Li-Sha G, Jiang-Hua R, et al: Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. J Cardiovasc Pharmacol 2008; 51: 92-98.
9. Louis A, Cleland JG, Crabbe S, et al: Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001; 3: 381-387.
10. Remme WJ, Torp-Pedersen C, Cleland JG, et al: Carvedilol protects better against vascular events than metoprolol in heart failure. Results from COMET. J Am Coll Cardiol 2007; 49: 963-971.
11. Wei S, Chow LT, Sanderson JE, et al: Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol 2000; 36: 276-281.
12. Olivetti G, Capasso JM, Meggs LG, et al: Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res 1991; 68: 856-869.
13. Pfeffer JM, Pfeffer MA, Braunwald E, et al: Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57: 84-95.
14. Cao WJ, Zhang YZ, Zhang DH, et al: Inhibition of NF-κB by mutant IκBα enhances TNF-α- induced apoptosis in HL-60 cells by controlling bcl-xL expression. Chin Med J (Engl) 2004; 117: 972-977.
15. Refsgaard HH, Tsai L, Stadtman ER, et al: Modifications of proteins by polyunsaturated fatty acid peroxidation products. Proc Natl Acad Sci USA 2000; 97: 611-616.
16. Sia YT, Lapointe N, Parker TG, et al: Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation 2002; 105: 2549-2555.
17. Sia YT, Parker TG, Liu P, et al: Improved post- myocardial infarction survival with probucol in rats: effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression. J Am Coll Cardiol 2002; 39: 148-156.
18. Adamy C, Mulder P, Khouzami L, et al: Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post- myocardial infarction failing heart rats. J Mol Cell Cardiol 2007; 43: 344-353.
19. Timmers L, Sluijter JP, van Keulen JK, et al: Toll- like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 2008; 102: 257-264.
20. Nian M, Lee P, Khaper N, et al: Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004; 94: 1543-1553.
21. Zimmet JM, Hare JM: Nitroso-redox interactions in the cardiovascular system. Circulation 2006; 114: 1531-1544.
22. Omura T, Yoshiyama M, Kim S, et al: Involvement of apoptosis signal-regulating kinase-1 on angiotensin II-induced monocyte chemoattractant protein-1 expression. Arterioscler Thromb Vasc Biol 2004; 24: 270-275.
23. Ferder L, Inserra F, Martinez-Maldonado M, et al: Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. Curr Hypertens Rep 2006; 8: 191-198.
24. Altavilla D, Deodato B, Campo GM, et al: IRFI 042, a novel dual vitamin E-like antioxidant, inhibits activation of nuclear factor-κB and reduces the inflammatory response in myocardial ischemia-reperfusion injury. Cardiovasc Res 2000; 47: 515-528.
25. Sun M, Dawood F, Wen WH, et al: Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 2004; 110: 3221-3228.
26. Henderson BC, Tyagi SC: Oxidative mechanism and homeostasis of proteinase/antiproteinase in congestive heart failure. J Mol Cell Cardiol 2006; 41: 959-962.
27. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839.